(Q50876710)

24 March 2018

title

A role for natural killer cells in the immunopathogenesis of multiple sclerosis. (English)

1 reference

24 March 2018

0 references

Kastrukoff LF

1

1 reference

24 March 2018

Morgan NG

2

1 reference

24 March 2018

Zecchini D

3

1 reference

24 March 2018

White R

4

1 reference

24 March 2018

Petkau AJ

5

1 reference

24 March 2018

Satoh J

6

1 reference

24 March 2018

Paty DW

7

1 reference

24 March 2018

publication date

1 June 1998

1 reference

24 March 2018

Journal of Neuroimmunology

published in

1 reference

24 March 2018

volume

86

1 reference

24 March 2018

page(s)

123-133

1 reference

24 March 2018

issue

2

1 reference

24 March 2018

Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Receptors for HLA class I molecules in human NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Clonal evidence for the induction of NKH1 on activated human thymocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Production of hematopoietic colony-stimulating factors by human natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Natural killer cells: their roles in defenses against disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Overview and perspectives: natural resistance mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-alpha 2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Surface markers on human b and t lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Towards a better definition of human leucocyte surface molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Enumeration of T, B and natural killer peripheral blood cells of patients with multiple sclerosis and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Introduction: NK cells: origin, receptors and specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Multiple sclerosis: in relapsing patients, immune functions vary with disease activity as assessed by MRI

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Natural killer cell activity in patients with multiple sclerosis given alpha interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Induction of TH1 and TH2 responses: a key role for the 'natural' immune response?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Absence of natural killer (NK) cell activity against oligodendrocytes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Cytolysis of oligodendrocytes is mediated by killer (K) cells but not by natural killer (NK) cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Lymphokine-activated killer (LAK) and adherent LAK (A-LAK) activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Characteristics of human large granular lymphocytes and relationship to natural killer and K cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Response of resting human peripheral blood natural killer cells to interleukin 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Biology of natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

A view to a kill: cytotoxic mechanisms of human polymorphonuclear leukocytes compared with monocytes and natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Natural killer cell number and activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

NK cell proliferation and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2898%2900014-9

7 January 2021

10.1016/S0165-5728(98)00014-9

Identifiers

DOI

1 reference

24 March 2018

PubMed ID

9663557

1 reference

24 March 2018